Biogen (BIIB) Stock Price, News & Analysis

Company Overview

Biogen Inc. is a biotechnology company focused on the discovery, development and delivery of therapies for neurological, autoimmune and rare diseases. The company’s marketed portfolio includes multiple sclerosis treatments such as Avonex, Tysabri (developed in collaboration with Elan Pharmaceuticals) and Tecfidera, as well as Spinraza for spinal muscular atrophy. In addition to its established products, Biogen offers Vumerity and Fampyra to address the needs of patients with various neurodegenerative and neuromuscular conditions.

Beyond its commercial portfolio, Biogen maintains an active research and development pipeline targeting Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease and other central nervous system disorders. The company has pursued innovative modalities including antisense oligonucleotides and monoclonal antibodies, often entering strategic partnerships to advance late-stage clinical candidates. Biogen’s commitment to neuroscience research is supported by collaborations with academic institutions and biotechnology firms around the world.

Founded in 1978 and headquartered in Cambridge, Massachusetts, Biogen operates in key biopharmaceutical markets across North America, Europe, Japan and emerging regions. The company’s global infrastructure encompasses research facilities, manufacturing sites and commercial offices, enabling it to serve patients and healthcare providers in more than 90 countries. Led by an executive management team with deep industry expertise, Biogen continues to invest in science-driven innovation aimed at transforming the standard of care for neurological and rare disease patients.

Key Stats

• Today's Range: $137.02 to $139.28
• 50-Day Range: $122.68 to $148.84
• 52-Week Range: $110.04 to $197.70
• Volume: 148,938 shs
• Average Volume: 1.56 million shs
• Market Capitalization: $20.06 billion
• P/E Ratio: 13.08
• Dividend Yield: N/A
• Price Target: $181.65
• Consensus Rating: Hold

Biogen Stock Analysis - MarketRank™

Biogen scored higher than 95% of companies evaluated by MarketBeat, and ranked 74th out of 951 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Hold

Consensus Rating

Biogen has received a consensus rating of Hold. The company's average rating score is 2.32, and is based on 10 buy ratings, 21 hold ratings, and no sell ratings.

Upside Potential

Biogen has a consensus price target of $181.65, representing about 30.4% upside from its current price of $139.31.

Amount of Analyst Coverage

Biogen has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 4.30%

Earnings Growth

Earnings for Biogen are expected to grow by 4.30% in the coming year, from $15.83 to $16.51 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Biogen is 13.32, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 282.06.

Price to Earnings Ratio vs. Sector

The P/E ratio of Biogen is 13.32, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 76.25.

Price to Earnings Growth Ratio

Biogen has a PEG Ratio of 1.11. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Biogen has a P/B Ratio of 1.21. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.23% of the float of Biogen has been sold short.

Short Interest Ratio / Days to Cover

Biogen has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Biogen has recently increased by 13.46%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Biogen does not currently pay a dividend.

Dividend Growth

Biogen does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.7 / 5
• Environmental Score: -1.82

Percentage of Shares Shorted

3.23% of the float of Biogen has been sold short.

Short Interest Ratio / Days to Cover

Biogen has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Biogen has recently increased by 13.46%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 1.04

News Sentiment

Biogen has a news sentiment score of 1.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 28 news articles for Biogen this week, compared to 27 articles on an average week.

Search Interest

54 people have searched for BIIB on MarketBeat in the last 30 days. This is an increase of 26% compared to the previous 30 days.

MarketBeat Follows

Only 4 people have added Biogen to their MarketBeat watchlist in the last 30 days. This is a decrease of -56% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Biogen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $369,150.00 in company stock.

Percentage Held by Insiders

Only 0.18% of the stock of Biogen is held by insiders.

Percentage Held by Institutions

87.93% of the stock of Biogen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

BIIB Stock Analysis - Frequently Asked Questions

How have BIIB shares performed this year?

Biogen's stock was trading at $152.92 on January 1st, 2025. Since then, BIIB shares have decreased by 8.9% and is now trading at $139.31.

How were Biogen's earnings last quarter?

Biogen Inc. (NASDAQ:BIIB) announced its quarterly earnings results on Thursday, July, 31st. The biotechnology company reported $5.47 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.93 by $1.54. The company's quarterly revenue was up 7.3% on a year-over-year basis.
Read the conference call transcript.

Does Biogen have any subsidiaries?

Biogen subsidiaries include these companies: Nightstar Therapeutics plc, Convergence Pharmaceuticals, TYSABRI, Stromedix Inc., Panima Pharmaceuticals AG, Syntonix Pharmaceuticals Inc., Fumapharm, and more.

Who are Biogen's major shareholders?

Top institutional shareholders of Biogen include Vanguard Group Inc. (11.79%), Primecap Management Co. CA (10.78%), State Street Corp (5.09%) and Geode Capital Management LLC (2.67%). Insiders that own company stock include Susan H Alexander, Eric K Rowinsky, Stephen A Sherwin, Stephen A Sherwin, Stephen A Sherwin, Ginger Gregory, Rachid Izzar and Priya Singhal.
View institutional ownership trends.

How do I buy shares of Biogen?

Shares of BIIB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Biogen own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Biogen investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Tesla (TSLA), Broadcom (AVGO) and Intel (INTC).

Company Calendar

• Last Earnings: 7/31/2025
• Today: 9/24/2025
• Next Earnings (Estimated): 10/29/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:BIIB
• CIK: 875045
• Web: www.biogen.com
• Phone: (617) 679-2000
• Fax: 617-679-2617
• Employees: 7,605
• Year Founded: 1978

Price Target and Rating

• Average Price Target for Biogen: $181.65
• High Price Target: $275.00
• Low Price Target: $118.00
• Potential Upside/Downside: +30.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.32
• Research Coverage: 31 Analysts

Profitability

• EPS (Trailing Twelve Months): $10.46
• Trailing P/E Ratio: 13.32
• Forward P/E Ratio: 8.80
• P/E Growth: 1.11
• Net Income: $1.63 billion
• Net Margins: 15.31%
• Pretax Margin: 17.98%
• Return on Equity: 13.85%
• Return on Assets: 8.32%

Debt

• Debt-to-Equity Ratio: 0.36
• Current Ratio: 2.50
• Quick Ratio: 1.79

Sales & Book Value

• Annual Sales: $9.68 billion
• Price / Sales: 2.11
• Cash Flow: $22.88 per share
• Price / Cash Flow: 6.09
• Book Value: $114.71 per share
• Price / Book: 1.21

Miscellaneous

• Outstanding Shares: 146,620,000
• Free Float: 146,351,000
• Market Cap: $20.43 billion
• Optionable: Optionable
• Beta: 0.11